Since there are different subtypes of depression, future investigation is warranted to test the more detail mechanisms of IDO1 in brain functional regulation and preclinical settings with human subjects and to validate the robustness of IDO1 intervention as a therapeutic strategy. The gene discussed is IDO1; the disease is depressive symptom measurement.